article thumbnail

Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering

Drug Target Review

However, the protein’s preclinical promise has not yet been replicated in clinical trials, where systemic administration is associated with dose-limiting toxicities and a narrow therapeutic index. Some approaches have already reached the clinical trial stage, with others not far behind. References: M; LWR.

article thumbnail

Bivamelagon

New Drug Approvals

3] [4] [5] As of March 2024, it is in phase 2 clinical trials. [1] “Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors” Biochemical Pharmacology. g, 86%, MC70 ). 1] References ^ Jump up to: a b “Rhythm Pharmaceuticals” AdisInsight. 13 March 2024. 23 January 2025. .;